# Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study

> **NCT02578394** · PHASE2,PHASE3 · COMPLETED · sponsor: **Mid and South Essex NHS Foundation Trust** · enrollment: 21 (actual)

## Conditions studied

- Gout
- Chronic Kidney Diseases

## Interventions

- **DRUG:** Anakinra 100mg and Placebo Depo-Medrone
- **DRUG:** Depo-Medrone 120mg and Placebo (Anakinra)

## Key facts

- **NCT ID:** NCT02578394
- **Lead sponsor:** Mid and South Essex NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2022-01-26
- **Final completion:** 2022-01-26
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2022-04-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02578394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02578394, "Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02578394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*